欢迎访问中国留学人才发展基金会!
热门关键字:  人才  留学  中国  走出去  留学事业部
当前位置:主页 > 抗疫行动 > 抗疫英雄谱 >

全球抗疫英雄谱——奋战在国际抗击新冠肺炎(COVID-19)一线的医护人员

时间:2020-07-31 13:55:51 来源:中国留学人才发展基金会 作者:宣传联络部

122

 

 

蒙塞夫·穆罕默德·斯劳依(Moncef Mohamed Slaoui):领导美国神速任务疫苗研发工作

 

 

美国科学家蒙塞夫·穆罕默德·斯劳依Moncef Mohamed Slaoui)是美国“神速任务”疫苗研发工作小组首席顾问,负责带领科研团队研发新冠疫苗和治疗方法。这位比利时裔美国研究员曾就读于哈佛医科大学,在塔夫茨大学医学院任教。毕业后,他在葛兰素史克疫苗研发部门担任负责人。美国卫生与公众服务部长亚历克斯·阿扎曾评价他是世界上经验最丰富,最成功的疫苗研发者之一。从业多年,斯劳依博士在免疫学领域取得了令人瞩目的成果,研发针对疟疾轮状病毒宫颈癌和肺炎球菌等多种病毒的疫苗。

斯劳依作为新冠疫苗研发小组的首席科学家,将通过与政府合作,使用广泛的研究和实验基础设施,带领科研小组充分利用研究计划和临床试验网络中的可用资源,以确保生产足够数量的安全有效疫苗当务之急是根据白宫新冠疫情应对工作组新制定的战略计划,发一种安全有效的疫苗,以防止感染扩散或疫情反弹。

尽管快速研发安全有效的疫苗是新冠疫情应对工作组的战略重点,但斯劳依的团队除了对新药进行广泛测试外,还鉴定和评估已经批准能够用于治疗新冠肺炎的其他药物的有效性。

斯劳依与许多科学家一致认为,在处理致病生物体的相关问题上,需要提高透明度。提高透明度是为了保护各级公共安全,并确保在紧急事件发生时立即采取补救措施。对于医学研究人员和学者而言,当务之急是要不惜一切代价避免各国在疫苗研发领域,出现不顾中国美国其他任何国家生物研究实验室安全的恶性竞争行为。 

 

 

Moroccan scientist heads Trump’s team to develop a coronavirus vaccine

 

The administration of US President Donald Trump has appointed Moroccan-born Belgian-American scientist Moncef Mohamed Slaoui as chief scientist of the committee tasked to develop coronavirus vaccines and treatments. Slaoui’s selection was based on his impressive academic and professional record and accomplishments in this field. 

Slaoui has a confirmed track record of impressive results in the field of immunology and the discovery of several vaccines, including those against malaria, rotavirus, cervical cancer and pneumococcus. He also had a successful managerial stint heading the vaccine department at the pharmaceutical giant GlaxoSmithKline between 2011 and 2016, during which the company succeeded in producing 24 new medicines and vaccines for advanced viruses. He also served on the board of directors of Moderna, the firm that conducted the first vaccine test used to treat a COVID-19 patient in America a few days ago. 

Born in 1959 in the city of Agadir in southern Morocco, Slaoui now resides in the United States. He realised early on that real strength in the future will not be connected to intercontinental ballistic missiles or slow-moving and range-restricted tanks, but rather to research labs and pharmaceutical and vaccine companies. 

Slaoui has an impressive academic track record. He left Morocco to France to pursue his university studies, then settled in Belgium where he studied molecular biology and graduated from the Free University of Brussels. He completed a PhD in immunology from the Free University of Brussels, and then migrated to the United States, where he completed his scientific and academic path in his field of specialisation by teaching and researching at Harvard Medical School. 

As chief scientist of the COVID-19 vaccine team, Slaoui will have access to extensive research and experimental infrastructure in the US with the aim of quickly developing experimental vaccines during the first stage of dosage and safety testing. He will work with government partners to ensure that any safe and effective vaccine will be manufactured in sufficient quantities. 

To move towards this goal, Slaoui and his committee will rely on available results and resources from the network of research programmes and clinical trials. The first priority for Trump’s team is to develop a safe and effective vaccine to stop the infection from spreading and prevent future outbreaks, in line with the new strategic plan of the White House Coronavirus Task Force, which represents a comprehensive and coordinated effort to develop effective biomedical tools to combat COVID-19. 

Slaoui will draw on his experience in the field to work with his team to adapt vaccines, treatments and methods previously used to treat the Middle Eastern Respiratory Syndrome (MERS) and other severe coronaviruses, such as SARS, and apply them to the current pandemic. 

Although developing an effective vaccine as quickly as possible is an important and strategic priority, Slaoui’s team will have to first identify and evaluate the effectiveness of drugs already approved for other diseases that have potential for treating COVID-19, in addition to extensive testing of new antivirals based on monoclonal antibodies. 

Compound vaccines are a critical way to enhance public health coverage through coronavirus immunisation. In this context, and based on his research and experience, Slaoui believes that without having five or six vaccines grouped in one dose, it will be difficult to enter the game of the vaccine industry. 

Despite Saloui’s appointment, the struggle continues over who will have the final say when it comes to manufacturing and marketing the new vaccine. The war against COVID-19 is a race for who will be first to corner the global strategic market of producing an effective and safe vaccine. Given the gravity and sensitivity of the new task force’s work, and given the visible conflict between Washington and Beijing, Slaoui will necessarily benefit from the official protocols of high-level security protection. 

Slaoui, however, agrees with a number of other scientists that there is a much greater need for transparency on issues related to dealing with disease-causing organisms because of the possibility of their accidental release. The goal of transparency is to protect public safety at all levels and ensure that remedial actions are immediately taken in the event of an accident. What is important for these scholars is to avoid at all costs the atmosphere of a dangerous and unethical competitiveness in this domain between major powers, without ensuring the safety of all biological research labs, whether in China, the US or any other country.

 

来源:The Arab Weekly, Salam Web, Ecoactu.ma

 

 

温馨说明:本栏目中文内容由我会根据来源处内容整理并翻译。

(责任编辑:宣传联络部)
关于我们 | 联系我们 | 网站地图 |版权声明
中国留学人才发展基金会 版权所有2010-2020
增值电信业务(ICP,SP)经营许可证 | 京ICP备10218477号-1 | 京公网安备11010502032309号